An example of the application of bioinformatics in new therapeutic advances is the development of novel designer targeted drugs such as imatinib mesylate (Gleevec).which interferes with the abnormal protein made in chronic myeloid leukaemia.(Imatinib mesylate was synthesised at Novartis Pharmaceuticals by identifying a lead in a high throughput screen for tyrosine kinase inhibitors and optimising its activity for specific kinases.)